Mexico Hemostats Market - Forecast(2024 - 2030)

Mexico Hemostats Market Overview

The Mexico Hemostats market size is estimated to reach $330 million by 2026. Furthermore, it is poised to grow at a CAGR of 5.6% over the forecast period of 2021-2026. Hemostats are medical instruments primarily used to address three core areas- to grasp and secure superficial fascia and wounds, clamp blood vessels for hemorrhage control or prevent blood loss, and lastly, it is an excellent tool for visualizing and exposing, and exploring the deeply affected wounds. Additionally, arterial forceps are used to withhold the bleeding, and hence, they also belong into the category of Hemostats. Fibrin sealants, a hemostatic agent, have been actively used for their superior anti-coagulation abilities. Moreover, it has been evaluated and agreed that fibrin provides a means of adjunctive anastomotic closure in a variety of surgeries across the domain. The increase in the cases of cardiovascular surgeries and the rise in fatal traumatic incidents and technological advancements are some of the factors driving the Mexico Hemostats Industry forward during the projected period of 2021-2026.

Mexico Hemostats Market Report Coverage

The report: “Mexico Hemostats Market Forecast (2021-2026)”, by Industry ARC covers an in-depth analysis of the following segments of the Mexico Hemostats Market.

• By Product Type- Thrombin, Oxidized Regenerated Cellulose, Collagen Based, Polysaccharide, Fibrin Sealants, Synthetic Sealants, Combination Sealants, Gelatin Based Hemostats, and Others.
• By Formulation- Matrix and Gel Hemostats, Sheet and Pad Hemostats, Sponge Hemostats, and Powder Hemostats. 
• By Application- Orthopedic Surgery, Gynaecological Surgery, Neurological Surgery, General Surgery, Cardiovascular Surgery, and Others. 
• By End Users- Hospitals, Ambulatory Surgical Centres, Specialty Clinics, and Others.

• The technological advancement associated with increased trauma and hemorrhage-related injury is a major contributor to driving the market forward. Moreover, the fatalities per 100,000 road accidents make it a hot spot for the hemostats market. Additionally, the R&D activities initiated by the government and private players are driving the markets forward.
• The challenge that the market must address is to control the costs of the end product and ease the clinical trials processes.
• A detailed analysis of the strengths, weaknesses, opportunities, and threats will be provided in the Mexico Hemostats market report.

Mexico Hemostats Market- End Users as (%) for 2020

For More Details on This Report - Request for Sample

Mexico Hemostats Market Segmentation Analysis – By Product Type

The Mexico hemostats market based on product type can be further segmented into Thrombin, Oxidized Regenerated, Collagen Based, Polysaccharide, Fibrin Sealants, Synthetic Sealants, Combination Sealants, Gelatin Based Hemostats, and Others. Thrombin hemostats held a dominant market share in the year 2020. It is owing to the natural characteristic exhibited by the following product class. Moreover, it has been in the market for decades. Furthermore, when added, the interaction between the thrombin of bovine and calcium chloride starts the process of hemostasis.

Moreover, the thrombin-based segment is estimated to be the fastest-growing, with a CAGR of 6.1% over the forecast period of 2021-2026. It is owing to the ability to convert fibrinogen into fibrin at a significant pace, which in turn helps in faster thrombus formulation. Additionally, recombinant human and bovine thrombin can be stored at room temperature in powder form, and after mixing it with chloride/ saline solution, their shelf life can increase up to 8-24 hours. Furthermore, a meta-analysis indicated that a thrombin-based hemostatic agent applied before wound closure or wound dressing decreased the chances of postoperative blood loss and additionally increased the transfusion rate without the risk of infection. Further, the porcine gelatine matrix can be combined with the thrombin hemostatic product to offer cost advantages.

Mexico Hemostats Market Segmentation Analysis – By End Users

The Mexico hemostats market segment based on the end-users can be further segmented into Hospitals, Ambulatory Surgical Centres, Specialty Clinics, and Others. The hospitals' segment held a dominant market share of 47% in the year 2020. It is owing to the recent government policy, which dictates that the number of beds available per 100,000 of the population should increase about 10-15%. Additionally, 145,544 beds hospital beds have been observed in the year 2020. As a result, the following capacity increased by up to 19% from the previous total of 2019.

Moreover, the hospital segment is estimated to be the fastest-growing, with a CAGR of 6.7% over the forecast period of 2021-2206. It is owing to the number and types of surgeries a hospital can perform. For example, government-run hospitals have all the surgeons’ classes specializing in orthopedic, gynecology, and general surgery. Furthermore, with the increasing bed numbers and private hospital players, the hemostats market is to be positively benefited.

Mexico Hemostats Market Drivers

The relative percentage increase in cesarean operations has driven the market growth

A study conducted by the researchers across the timeline from 2010 to 2019 indicated a relative increase in the c- section operations that took place in the country of Mexico. As per the fact sheets, a 4.4% increase in the average births was recorded, and a relative decrease was noticed in the vaginal deliveries by 3.5%. The following figures indicate the ready use of C-Section operation in the country, and as per WHO, the country is amongst the top 10 places for C-sections. There are various causes of hemorrhage at the time of cesarean delivery, and they are divided mainly into bleeding from the separated surface of the placenta and atonic bleeding. Therefore, combining hemostatic techniques such as balloon tamponade, compression suture, arterial ligation, transarterial embolization (TAE), and hysterectomy is essential for successful hemostasis.

Technological developments across the field and product launches to address the rising need will be the leading driver for the following market

Companies globally and in countries like Mexico are actively finding better solutions and advancements in the hemostats being used. Moreover, they are trying to reduce the chances of infections and increase the percentage of acceptability by the body. For example, Arista AH launched a 100% plant-based absorbable surgical hemostat powder. Moreover, the products are advised to be used in cases when the capillary, venous, and arteriolar conservative procedures have failed. Moreover, PuraStat received the government’s nod to manufacture an absorbable hemostat.

Mexico Hemostats Market Challenges

The cost associated with better-equipped hemostats is higher than the traditional hemostats, the following acts as a challenge for the market to address

A study was conducted by the Mexican Public Health Care Institution to find out the economic benefits which can be reaped by using advanced hemostatic agents. Moreover, the results indicated that the newer technology-equipped hemostats provide better yield and customer satisfaction, but the cost associated with the traditional hemostats was recorded to be 3-4% higher. Furthermore, the results indicated that the total cost of staying in the hospital was reduced by a small percentage when the modern hemostats were used, but those were non-significant. Additionally, a reduction in the per capita income was recorded, it was 3% lower than in 2019.

Mexico Hemostats Market Competitive Landscape

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Mexico hemostats Market. The top 10 Mexico Hemostats market companies include:

1. Baxter
2. Integra Life Sciences.
3. Stryker
4. CryoLife
5. Johnson and Johnson
6. Pfizer
7. Medtronic
8. B & D
9. Arista
10. PuraStat

Recent Developments

• In July 2021, Medcura Inc launched a new product known as Rapid Seal. The following is an antibacterial hemostatic gel, and additionally, the product is transparent and hence allowing the doctor to see the injury.
• In February 2021, EndoClot received a nod from the Mexican clinical trial authorities and US FDA for its Polysaccharide Hemostatic System. The following would help in the GI-based surgery.

Relevant Titles

Hemostats Market- Forecast (2021-2026)

Report Code- HCR 1222

European Hemostats Market- Forecast (2021-2026)

Report Code- HCR 1212

For more Lifesciences and Healthcare Market reports, please click here